Kirin (KNBWY)
(Delayed Data from OTC)
$14.60 USD
-0.19 (-1.28%)
Updated Apr 24, 2024 03:46 PM ET
5-Strong Sell of 5 5
D Value B Growth F Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
KNBWY 14.60 -0.19(-1.28%)
Will KNBWY be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for KNBWY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KNBWY
Kirin Holdings Co. (KNBWY) Upgraded to Strong Buy: Here's Why
Take the Zacks Approach to Beat the Market: NVIDIA, Novo Nordisk, Magenta in Focus
KNBWY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Investors Undervaluing Kirin (KNBWY) Right Now?
KNBWY vs. NAPA: Which Stock Is the Better Value Option?
Should Value Investors Buy Kirin (KNBWY) Stock?
Other News for KNBWY
OLLY Launches New Cognitive Health Supplements With 'Focus Buddies Brainy L'OLLY Pops' Including Cognizin® Citicoline
ENCORE Introduces Innovative Beverage Mixes Featuring Science-Backed Cognizin® and IMMUSE™ for Cognitive and Beauty Support
Warning: KNBWY is at high risk of cutting its dividend
First Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of Mycosis Fungoides and Sézary Syndrome
First Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of Mycosis Fungoides and Sézary Syndrome